A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Inclusion Criteria:

• Age 18-40 years (inclusive of threshold), gender is not limited.

• Subjects have an Investigator's Global Assessment (IGA) score of 3 or 4 (i.e.,moderate or severe).

• Men of childbearing potential and women of childbearing potential willing to useeffective contraception from the time of signing the informed consent until 3 monthsafter the last dose of the investigational drug; women of childbearing potentialinclude premenopausal women and women within 2 years of menopause. Women ofchildbearing potential must have a negative pregnancy test result within ≤ 7 daysprior to the first dose of the investigational drug.

• Subjects are willing and able to complete the study, are able to understand andcomply with the study requirements, adhere to the study required restrictions andrelated tutorials, use the investigational drug as prescribed, and are followed upaccording to the study plan.

Exclusion Criteria:

• Known hypersensitivity to the ingredients of ASC40 (Denifanstat) tablets or to anyof the excipients.

• Presence of cystic acne at screening.

• Patients with secondary acne such as occupational acne (e.g., chloracne) andcorticosteroid-induced secondary acne (e.g., chloracne or drug-induced acne)

• Patients with other significant coexisting skin conditions that may affect theevaluation of facial acne efficacy or require co-treatment, such as solardermatitis,psoriasis, seborrheic dermatitis, rosacea, folliculitis, eczema, etc..

• Thicker facial hair, which has been assessed by researchers to impede accurateassessment of acne vulgaris grades or lesion counts